Option to give second-line ixazomib with lenalidomide and dexamethasone for patients who are neither refractory to previous proteasome inhibitor-based treatment nor to lenalidomide- based treatment if contained within the first line of therapy already received


This is an additional interim treatment change option endorsed by NHS England for the Covid-19 pandemic.